RxDoctor Payments Data

Glenn Hammer, MD

Infectious Disease · New York, NYNPI 1750333498

Payments from drug & device makers

$3,183in general payments, 2019–2025

Across 150 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$939
  • Merck$769
  • Viiv Healthcare Company$546
  • Johnson & Johnson$300
  • Melinta Therapeutics, LLC$139
  • Janssen Products, LP$99
  • plus $390 from 12 others

What the payments were for

  • Food & beverage$3,07397%
  • Education$1103%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,183 in reported general payments places this provider in the 75th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York

Medicare billing

Part B allowed, 2024
$135,677
Medicare patients
278
Services billed
1,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RukobiaFostemsavir Tromethamine15$154,162
TivicayDolutegravir Sodium29$99,950
TriumeqAbacavir/Dolutegravir/Lamivudi24$87,913
Maraviroc43$56,220
IsentressRaltegravir Potassium26$49,607
BiktarvyBictegrav/Emtricit/Tenofov Ala12$48,022
EdurantRilpivirine Hcl25$35,268
DescovyEmtricitabine/Tenofov Alafenam13$28,168
Darunavir28$20,503
Etravirine14$16,352
EliquisApixaban13$11,674
Fosamprenavir Calcium12$11,289
Ritonavir30$8,491
XareltoRivaroxaban11$8,404
Lamivudine-ZidovudineLamivudine/Zidovudine12$6,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyRukobia, Tivicay, Triumeq$546$342,02568 claims
GileadBiktarvy, Descovy$939$76,19025 claims
MerckIsentress$769$49,60726 claims
PfizerEliquis$66$11,67413 claims
Johnson & JohnsonXarelto$300$8,40411 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$18$84453 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 799 infectious disease providers in New York.

Other infectious disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →